Диссертация (1140761), страница 23
Текст из файла (страница 23)
1997. - Vol. 24, N 2. - P. 328 - 332.123. Hiepe F. CREST-syndrome // Art. Rheum. 1995. - Vol. 20, N 3. - P. 112.124. Нiremath NC, Madan Mohan NT, Srinivas C, Sangolli PM, Srinivas K, VrushaliVD. Juvenile localized scleroderma with autoimmune thyroid disorder.
Indian JDermatol. 2010.-Vol.55, N.3-P.308-309.125. Hudson M, Rojas-Villarraga A, Coral-Alvarado P, López-Guzmán S, MantillaRD, Chalem P; Canadian Scleroderma Research Group; Colombian SclerodermaResearch Group, Baron M, Anaya JM. Polyautoimmunity and familial autoimmunityin systemic sclerosis. Autoimmun.2008.-Vol.31, N.2, P.156-159.126.
Ihn H., Sato S., Fujimoto M. et al. Demonstration of interleukin-4 andinterleukin-6 in sera from patients with localized scleroderma // Arch. Dermatol. Res.-1995. Vol. 287, N 2. - P. 93 - 97.127. Ingegnoli F., Trabattoni D., Sarella M. et al. Distinct immune profilescharacterize patients with diffuse or limited systemic sclerosis // Clin.
Immunol.2003. -Vol. 108, N 1.-P. 21 -28.128. Janeway С.A., Travers P. Immunobiology: immune system health and disease //L., San Francisco, Philadelphia: Current Biology Ltd., 1995. 640 p.129. Jorde R. "Subclinical" thyroid disease // Tidsskr. Nor. Laegeforen. 2002.
-Vol.17, N9.-P. 938-940.130. Kadono Т., Kikuchi K., Ihn H. et al. Increased production of interleukin 6 andinterleukin 8 in scleroderma fibroblasts // J. Rheumatol. 1998. - Vol. 25, N 2. - P.296-301.151131. Kahaleh M.B. Soluble immunologic products in scleroderma sera // Clin.Immunol. Immunopathol. 1991.-Vol. 58, N l.-P. 139- 144.132.
Kantor T.V., Friberg D., Medsger T.A. Cytokine production and serum levels insystemic sclerosis // Clin. Immunol. Immunopathol. 1992. - Vol. 65, N 3. - P. 278285.133. Keenan G.F., Ostrov B.E., Goldsmith D.P., Athreya B.H. Rheumatic symptomsassociated with hypothyroidism in children // J. Pediatr. 1993. - Vol.
123, N 4.-P.586-588.134. Kırmızıbekmez H, Yeşiltepe Mutlu RG. Atypical Presentation of Hashimoto'sDisease in an Adolescent: Thyroid-Associated Ophthalmopathy. J Clin Res PediatrEndocrinol. 2014.-Vol.6, N.4, P.262-265.135. Koumakis E, Dieudé P, Avouac J, Kahan A, Allanore Y. Familial autoimmunityin systemic sclerosis - results of a French-based case-control family study. // JRheumatol. 2012.-Vol.39, N.3, P.532-538.136. Kreuter A., Gambichler T., Breuckmann F., Rotterdam S. et al. Pulsed high-dosecorticosteroids combined with low-dose methotrexate in severe localizedscleroderma., 2005.-Vol.141,N.7-P.847-852.137. Kurasawa K., Hirose K., Sano H.
et al. Increased interleukin-17 production inpatients with systemic sclerosis //Arthr. and Rheum. 2000. - Vol. 43, N. 11. - P. 255263.138. Kurt T.L. Sclerodermia in long-term employees at a semiconducor plant // J.Toxicol. Clin. Toxicol.-2004.-Vol. 42, N 5.- P. 810 - 811.139. Kyle U.G, Shekerdemian L.S, Coss-Bu J.A. Growth failure and nutritionconsiderations in chronic childhood wasting diseases.-2015.-Vol.30, N.2 .-P.227-238.140. Lazúrová I, Benhatchi K.
Autoimmune thyroid diseases and nonorgan-specificautoimmunity. Pol Arch Med Wewn. 2012;122 Suppl 1:55-9.141. Le Roy E.C. Raynauds phenomenon, scleroderma, overlap syndromes and otherfibrosis syndromes // Current Opinion in Rheum. 1993. - Vol. 4. - P. 821 - 824.142. Leonhardt J.M., Heymann W.R. Thyroid disease and the skin // Dermatol.
Clin.2002. - Vol. 20, N 3. - P. 473 - 481.152143. Lis A., Brzezinska-Woislo L. Interleukin-2 and IL-6 in serum marked of diseaseprogression in systemic sclerosis // Pol. Merkuriusz Lek. 2001. - Vol. 11, N 63.-P.206-209.144. Livi R, Teghini L., Pignone A., Generini S., Matucci-Cerinic M., Cagnoni M.Renal fimctional reserve in impaired patients with systemic sclerosis without clinicalsigns of kidney involvement//Ann. Rheum.
Diseases. -2002. Vol. 61, N 8. -P. 682686.145. Lyson K., McCann S.M. The effect of interleukin-6 on pituitary hormonerelease in vivo and in vitro // Neuroendocrinology. 1991. - Vol. 54. - P. 262 - 266.146. Ludgate M., Emerson CH. Metamorphic thyroid autoimmunity. Thyroid.2008.Vol. 18, P.1035-1037.147. Manolios N., Dunckley H., Chivers T. et al. Immunogenetic analysis of 5families with multicase occurrence of scleroderma and/or related variants // J.Rheumatol.
1995. - Vol. 22. - P. 85 - 92.148. Marcovecchio M. L., Mohn A., Chiarelli F. Inflammatory cytokines and growthin childhood // Curr. Opin. Endocrinol. Diabetes Obes. 2012. Vol. 19. N 1. P. 57‒62.149. Martinez-Gordeo E., Fonseca M., Aguilar Leon D.E., Padilla A. Juvenalsystemic sclerosis // J. Rheumatol. 1993. - Vol. 20. - P. 405 - 406.150. Mayorquin F.J., Mclurley T.L., Levernier J.E., Progression childhood linearscleroderma to fatal systemic sclerosis // J. Rheumatol. 1994. - Vol. 21. N.10. - P.1955- 1957.151.
Mier R., Ansell В., Hall M.A. et al. Long term follow-up children with mixedconnective tissue disease // Lupus. 1996. - Vol. 5. - P. 221 - 226.152. Mouthon L., Garsia De La Pena-Lefebvre P., Chanseaud Y. et al. Pathogenesisin systemic scleroderma: immunological aspests // Ann. Med. Interne (Paris).-2002.Vol. 153, N3,-P. 167- 178.153. Nakamura K., Saiton A., Yasaka N. et al. Molecular mechanism involved inmigration of epidermal dendritic cells in the skin // J. Investig. Dermatol. Symp. Proc.-1999.-Vol. 4, N2.-P.
169-172.153154. Neiko I.M., Iat Syshyn R.I. Role of interleukin-1 and IL-2 in the pathogenesis insystemic sclerosis // Fiziol. Zhurn. 2002. - Vol. 48, N 1. - P. 56-61.155. Ohye H, Nishihara E, Sasaki I, Kubota S, Fukata S, Amino N, Kuma K,Miyauchi A. Four cases of Grave’s diseasewhich developed after painfulHashimoto’s thyroiditis. Intern Med. 2006; 45: 385-99.156. Papanicolaou D.A., Tsigos C., Torpy D.J., Defensor R., Thompson В., ChrousosG.P. Recombinant interleukin-6 effects on pituitary secretion in humans Abstract. // J.Invest. Med.
1996. - Vol. 44. - P. 266.157. Patrick M.R., Kirkham B.W., Graham M. et al. Circulating IL-1 beta and solubleIL-2 receptor evalution as markers of disease activity in scleroderma // J. Reumatol.1995. - Vol. 22, N 4. - P. 654 - 658.158. Paul W.E. IL-4: a prototype immunoregulatory lymphokine // Blood. -1991.Vol. 77.-P. 1859- 1870.159. Pieri L., Domenici L., Romagnoli P.
Langergans cell differentiation: a tree actplay // Ital. J. Anat. Embriol. 2001. - Vol. 106, N 1. - P. 47 - 69.160. Pober J.S., Cotran R.S. Cytokines and endotelial cell biology // Physiol. Rev.1990. - Vol. 70. - P. 427 - 451.161. Robazzi .C,Adan L.F. Autoimmune thyroid disease in patients with rheumaticdiseases// Rev Bras Reumatol. 2012. Vol. 52, N.3-P.417-430.162. Rosenberg A.M., Uxeil Y., Krafchik B.R. et al. Antinuclear antibodies inchildren with localized scleroderma // J. Rheumatol. 1995.
- Vol. 22. - P. 2337 2243.163. Sato S., Hanakawa H., Hasegawa M. et al. Levels of interleukin-12, a cytokineof type 1 helper T cells, are elevated in sera from patients with systemicsclerosis// J.Reumatol. 2000. - Vol. 27, N 12. - P. 238 - 242.164. Sato S., Hanakawa H., Takehara K. Serrum Levels of 11-6 And IL-10 correlatewith total skin thickness score in patients with systemic sclerosis // J. Dermatol.
Sci.2001. -Vol. 27, N2.-P. 140-146.165. Sävendahl L. The effect of acute and chronic stress on growth // EndocrinolMetab Clin North Am. 2012. Vol.41.N.4.p. 747-59.154166. Shafferman A., Fontaine K. R., Cron R. Q., Beukelman T. Changes in bodymass index in children with juvenile idiopathic arthritis treated with tumor necrosisfactor inhibitors //J. Rheumatol. 2014. Vol.41.N1.p. 113-118.167.
Shiff N.J., Brant R., Guzman J., Cabral D.A et al. Glucocorticoid-RelatedChanges in Body Mass Index among Children and Adolescents with RheumaticDeseases// Artritis Care Res (Hooken).2013. Vol 65.N1.p 113-121.168. Slominski A., Wortsman J., Kohn L. et al. Expression of HypothalamicPituitary-Thyroid Axis Reolated Genes in the Human Skin // J.
Inves. Dermatol.2002. -Vol. 119.-P. 1449- 1455.169. Snapper C.M. et al. Induction of IgG3 secretion by interferon gamma: a modelfor T-cell independent class switching response to T-cell independent type 2antigens//J. of Ex. P. Med. 1992. - Vol. 175, N5.-P. 1367- 1371.170. Stuart R.A., Littelwood A.J., Maddison P.J. et al. Elevated serum interleukin-бlevels associated with active disease in systemic connective tissue disorders // Clin.Exp. Rheumatol. 1995. - Vol.
13, N 1. - P. 17 - 22.171. Surks M.I., Ocampo E. Subclinical thyroid disease // Amer. J. Med. 1996. - Vol.100, N2.-P. 217-223.172. Szegedi A., Czirjak L., Unkeless J.C. et al. Serum cytokine and anti Fe-gammaR autoantibody measurements in patients with systemic sclerosis // Acta DermatoVenerol. 1996. - Vol. 76, N 1. - P. 21 - 23.173. Szymanska-Jagiello W., Musiej-Nowakovska E., Kwitkowska M.W. Clinicalfeatures of scleroderma in children // XII Congr. Polish Reum. Society.
1996. -Vol.XXXIV, N. 2-3.-P. 713-714.174. Tagoe C.E, Zezon A, Khattri S. Rheumatic manifestations of autoimmunethyroid disease: the other autoimmune disease//J Rheumatol. 2012.-Vol.36, N.6,P.1125-1129.175. Tagoe C.E, Zezon A, Khattri S,Castelalnos P. Rheumatic manifestations ofeuthyroid, anti-thyroid antibody-positive patients// Rheumatol Int. 2013.-Vol. 33,N.7-P.1745-1752.155176. Tsigos С., Papanicolaou D.A., Defensor R., Mitsiadis C.S., Kyrou I., ChrousosG.P. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretionand energy expenditure // Neuroendocrinology.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
